TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35484817
Drug: Twice-daily enoxaparin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily enoxaparin
Study: 33818939
Drug: Hydrophilic nutrients
Normalized name: PSYLLIUM HYDROPHILIC MUCILLOID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrophilic nutrients (BESTFertil dietary supplement, 4 capsules per day)
Study: 33818939
Drug: Lipophilic nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipophilic nutrients (dietary supplement 'BrudiPlus', 3 capsules per day)
Study: 34478166
Drug: Niraparib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib (200 mg once daily) plus Pembrolizumab (200 mg every 3 weeks) in cohort 1
Study: 34478166
Drug: Niraparib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib (200 mg once daily) plus Pembrolizumab (200 mg every 3 weeks) in cohort 2
Study: 34016868
Drug: Lidocaine 4%
Normalized name: Lidocaine 4% Patch
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 4% topical solution
Study: 35507334
Drug: Nomacopan, 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomacopan, 90 mg subcutaneously on day 1 and 30 mg subcutaneously daily until day 42
Study: 34626008
Drug: Low-dose rhEPO
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rhEPO (40 IU/kg)
Study: 34626008
Drug: rhEPO micro-doses
Normalized name: docusate Enema [Colace Micro-Enema]
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO micro-doses (900 IU)
Study: 34626008
Drug: Washout phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Washout phase after rhEPO administration
Study: 36001436
Drug: Alcohol administration
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administration (oral and intravenous, variable and fixed doses)
Study: 35708758
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (targeted antifungal therapy driven by culture results)
Study: 33431819
Drug: CB1 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CB1 antagonist AM281
Study: 32530339
Drug: Control (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (routine treatments only)
Study: 35389961
Drug: High-dose Levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Levothyroxine
Study: 35389961
Drug: High-dose Methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Methylprednisolone
Study: 35389961
Drug: Combo (High-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combo (High-dose Levothyroxine + High-dose Methylprednisolone)
Study: 35389961
Drug: Control (No
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (No hormonal therapy)
Study: 35490603
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL drain removal
Study: 35490603
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL drain removal
Study: 35490603
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL drain removal
Study: 34088920
Drug: Regular calcium
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular calcium + 5 x 10^8 CFU/day L. casei CRL 431 (Casei)
Study: 35209942
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day probiotic cheese
Study: 32713421
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy after 6 weeks
Study: 32713421
Drug: CPAP titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP titration
Study: 34309665
Drug: Standard arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard arm (bevacizumab administered on the same day as chemotherapy)
Study: 34309665
Drug: Experimental arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental arm (bevacizumab administered 4 days before chemotherapy)
Study: 33189161
Drug: SNG001 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNG001 (6 MIU) inhaled daily for 14 days
Study: 33189161
Drug: Placebo inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhaled daily for 14 days
Study: 35998039
Drug: Nicotinamide Riboside
Normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide Riboside (1000 mg) + Pterostilbene (200 mg)
Study: 33871071
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of topical and oral glutathione
Study: 33871071
Drug: Topical glutathione
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glutathione
Study: 34247632
Drug: Standard prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prednisolone (1 mg/kg/day)
Study: 34247632
Drug: Reduced prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced prednisolone (0.5 mg/kg/day) and alfacalcidol (0.5 μg/day)
Study: 33171595
Drug: Probiotic plus
Normalized name: CVS Advanced Probiotic Plus Fiber Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic plus biotin treatment
Study: 36789614
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant
Study: 36801466
Drug: Sirolimus therapy
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus therapy
Study: 36709533
Drug: Agalsidase beta
Normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Agalsidase beta treatment
Study: 37460214
Drug: Longer time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer time to treatment
Study: 37378404
Drug: Ambrisentan treatment
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ambrisentan treatment
Study: 33410093
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 30/70 (BIAsp 30)
Study: 36301572
Drug: Olaparib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (200 mg twice daily)
Study: 33517185
Drug: Imatinib discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib discontinuation
Study: 33483802
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine infusion
Study: 38913933
Drug: Standard neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard neoadjuvant chemotherapy
Study: 34120312
Drug: Dacomitinib 45
Normalized name: dacomitinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib 45 mg QD
Study: 39014980
Drug: Disengagement coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disengagement coping (e.g., avoidance)
Study: 32858478
Drug: Prenatal exposure
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal exposure to chemotherapy
Study: 38484432
Drug: Bosutinib 500
Normalized name: bosutinib 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 500 mg once daily
Study: 37368512
Drug: Lower insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lower insulin sensitivity
Study: 37295336
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone Replacement Therapy (GHRT)
Study: 39691290
Drug: DAA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAA treatment
Study: 34748572
Drug: Nifurtimox-eflornithine combination
Normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifurtimox-eflornithine combination therapy (NECT)
Study: 34015791
Drug: Focal Electrically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal Electrically Administered Seizure Therapy (FEAST)
Study: 32453640
Drug: DA-EPOCH-R therapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-EPOCH-R therapy
Study: 33470063
Drug: Niraparib 300
Normalized name: niraparib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 300 mg/day
Study: 35075289
Drug: Lentiviral gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lentiviral gene therapy
Study: 39552592
Drug: Calcium Channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Channel Blockers
Study: 39773004
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) rituximab
Study: 39773004
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) rituximab
Study: 38332651
Drug: Hydroxyurea at
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea at maximum tolerated dose (MTD)
Study: 36146760
Drug: Direct-acting antivirals
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antivirals (DAAs)
Study: 37246348
Drug: Blinatumomab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab treatment
Study: 39005691
Drug: Debulking chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debulking chemotherapy
Study: 34078259
Drug: OnabotulinumtoxinA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: OnabotulinumtoxinA treatment
Study: 32192746
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) at 2 years
Study: 33139350
Drug: Laronidase enzyme
Normalized name: Laronidase
DrugBank: Laronidase (DB00090)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Laronidase enzyme replacement therapy (ERT)
Study: 36166340
Drug: Triple antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antithrombotic therapy
Study: 34238024
Drug: Subcutaneous adipose
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous adipose tissue (SAT)
Study: 37295810
Drug: Pipeline Embolization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipeline Embolization Device (PED) treatment
Study: 36301338
Drug: Daratumumab 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab 8 mg/kg
Study: 32532858
Drug: WEB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: WEB treatment
Study: 37141294
Drug: pembrolizumab 2
Normalized name: pembrolizumab 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab 2 mg/kg
Study: 34863270
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of therapies
Study: 34800495
Drug: Morphine consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine consumption
Study: 39441901
Drug: Ibrutinib therapy
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib therapy
Study: 33932130
Drug: Dabrafenib 150
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib 150 mg twice daily
Study: 38446574
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy (GT)
Study: 38421404
Drug: Venetoclax monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax monotherapy
Study: 33630063
Drug: Sipuleucel-T treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sipuleucel-T treatment
Study: 37722087
Drug: CC-115
Normalized name: CC-115
DrugBank: CC-115 (DB12740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-115
Study: 37358640
Drug: Idelalisib therapy
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idelalisib therapy
Study: 36548028
Drug: Digital Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital Medicine System (DMS)
Study: 39158832
Drug: Per-oral endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per-oral endoscopic myotomy (POEM)
Study: 37316692
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg orally once daily
Study: 36958766
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg two times per day
Study: 36958766
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg two times per day
Study: 37955849
Drug: Hybrid closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid closed-loop (HCL) insulin delivery system
Study: 35291351
Drug: Metreleptin therapy
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metreleptin therapy
Study: 35846221
Drug: CC-122
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-122
Study: 39290861
Drug: Disease-modifying therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying therapies (DMTs)
Study: 32320048
Drug: Pembrolizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (10 mg/kg every 2 weeks for up to 2 years)
Study: 33404519
Drug: 0.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/day entecavir
Study: 39555240
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitor therapy
Study: 33359404
Drug: Avelumab 10
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 10 mg/kg
Study: 37848867
Drug: Long-term antiretroviral
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term antiretroviral therapy (ART)
Study: 32427579
Drug: Atezolizumab (anti-PD-L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (anti-PD-L1 therapy)
Study: 35164991
Drug: MenB-FHbp vaccine
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenB-FHbp vaccine
Study: 32224030
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitors (GPIs)
Study: 37331992
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 or 10 mg BID
Study: 38335386
Drug: Integrative Korean
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Korean medicine treatment
Study: 35929414
Drug: EGFR tyrosine
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EGFR tyrosine kinase inhibitors (EGFR-TKIs)
Study: 32534242
Drug: Dabrafenib 150
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib 150 mg twice daily and trametinib 2 mg once daily
Study: 36599698
Drug: Serum NF-L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum NF-L
Study: 38828959
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg osimertinib once daily
Study: 37273449
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules for six months
Study: 35677318
Drug: Cabazitaxel 20
Normalized name: cabazitaxel 20 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel 20 mg/m²
Study: 37940142
Drug: Live zoster
Normalized name: Varicella zoster vaccine (live/attenuated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live zoster vaccine
Study: 35026142
Drug: Sofosbuvir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (400 mg) and velpatasvir (100 mg) once daily for 12 weeks
Study: 37261654
Drug: Adjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant endocrine therapy (AET)
Study: 38885481
Drug: CD19 CAR
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19 CAR T-cell therapy
Study: 39239186
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal oxygen (HFNO) therapy
Study: 36000434
Drug: LDL-C <70
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C <70 mg/dL
Study: 39181168
Drug: Direct-acting antiviral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antiviral agents
Study: 32318647
Drug: MLE4901 (NK3R
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLE4901 (NK3R antagonist)
Study: 34506666
Drug: Icatibant treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icatibant treatment
Study: 36093129
Drug: Non-vitamin K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-vitamin K antagonist oral anticoagulants (NOACs)
Study: 38467716
Drug: Cochleural Alternating
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochleural Alternating Acoustic Beam Therapy (CAABT)
Study: 34515993
Drug: Adjuvant S-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant S-1 chemotherapy
Study: 35483358
Drug: EGFR inhibitors
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR inhibitors
Study: 34255353
Drug: Decitabine 20
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine 20 mg/m²
Study: 39123434
Drug: TPF induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF induction chemotherapy (docetaxel, cisplatin, and 5-fluorouracil)
Study: 32000408
Drug: Interventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventional treatment
Study: 36696843
Drug: Treatment type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment type
Study: 38330380
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation therapy (CCRT)
Study: 37276084
Drug: Behavioral activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral activation therapy (BA)
Study: 37890960
Drug: Xylitol syrup
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylitol syrup
Study: 33761887
Drug: Beliefs about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beliefs about medications
Study: 34622233
Drug: Tocilizumab (IL-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (IL-6 receptor antibody)
Study: 35362522
Drug: Direct-acting antiviral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antiviral therapy
Study: 36063832
Drug: Azacitidine 75
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75 mg/m²
Study: 39012226
Drug: Control group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group, treatment not specified
Study: 38010394
Drug: Talazoparib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib (1 mg/day)
Study: 35773640
Drug: Rehabilitation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation treatment
Study: 35926961
Drug: Biological prosthesis
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological prosthesis
Study: 33961488
Drug: Lenvatinib 24
Normalized name: lenvatinib 24 MG Daily Dose 30 Day Supply Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 24 mg once daily
Study: 34660853
Drug: Burosumab treatment
Normalized name: Burosumab
DrugBank: Burosumab (DB14012)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Burosumab treatment
Study: 32649919
Drug: Low-dose chest
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chest CT (LDCT) screening
Study: 38049621
Drug: Nonavalent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonavalent vaccine
Study: 33836153
Drug: Treatment-related death
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related death
Study: 36130508
Drug: Anti-PD-1 treatment
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 treatment
Study: 32430709
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g OGTT
Study: 32430709
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g OGTT
Study: 34973207
Drug: Etonogestrel implants
Normalized name: etonogestrel Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etonogestrel implants
Study: 38135371
Drug: Intravenous decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous decitabine
Study: 35588166
Drug: Broad-spectrum antibiotics
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum antibiotics (AB+)
Study: 36348206
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
Study: 36656302
Drug: Osimertinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib treatment
Study: 32107887
Drug: Analytical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analytical treatment interruption (ATI)
Study: 32277401
Drug: Dulaglutide (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide (both doses)
Study: 33770805
Drug: OnabotulinumtoxinA injection
Normalized name: onabotulinumtoxinA Injection
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: OnabotulinumtoxinA injection (100 units)